Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Giovanni Rotondo – page 16

263 clinical trials in San Giovanni Rotondo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Giovanni Rotondo at a glance
263
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

263 trials in San Giovanni Rotondo

Open in trial search

Acute myeloid leukaemia

Not recruiting

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Neuraxpharm Pharmaceuticals S.L.

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Rectal cancer

Not recruiting

Study on Valproic Acid with Bevacizumab and Oxaliplatin/Fluoropyrimidine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Ovarian cancer

Not recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute lymphocytic leukaemia

Not recruiting

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Relapsing multiple sclerosis

Not recruiting

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Giovanni Rotondo

What the registry says about research in the country

01 Gastrointestinal Oncology

Clinical research focusing on metastatic colorectal cancer and gastroesophageal cancers, evaluating novel combination therapies and targeted treatments.

  • Advanced colorectal cancer treatments
  • HER2-positive gastric cancer therapies
  • Targeted molecular therapies
02 Inflammatory Bowel Disease

Studies examining innovative treatments for Crohn's Disease and Ulcerative Colitis, testing new therapeutic combinations and treatment strategies.

  • Novel biological therapies
  • Combination treatment approaches
  • Disease remission strategies
03 Hematologic Malignancies

Research initiatives in acute myeloid leukemia, multiple myeloma, and other blood cancers, exploring innovative therapeutic approaches.

  • Targeted leukemia treatments
  • Novel drug combinations
  • Immunotherapy approaches
04 Breast and Urological Cancers

Investigations into early breast cancer treatments and therapies for prostate cancer, with focus on hormone-responsive diseases.

  • Endocrine therapy optimization
  • Advanced prostate cancer treatments
  • Targeted therapeutic approaches
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.